cancer immunortherapy

News
OpdivoLarge

BMS suffers further setback in lung cancer

Bristol-Myers Squibb will not pursue early FDA filing for its Opdivo plus Yervoy combination in first line lung cancer – news which sent shares down more than 10% on Friday.